Because IL-8, through engagement with its receptors CXCR1/2, is a well-known driver of the stemness properties of the highly tumorigenic and resistant to cancer therapy sub-populations of so-called cancer stem cells [61,62,63], it is tempting to suggest that IL-8- or CXCR1/2-neutralizing antibodies might be therapeutically relevant for the clinical management of particular subsets of ER-positive/HER2-negative luminal breast carcinomas overexpressing the HER3 ligand HRG. Here, HRG is linked to breast carcinoma.